Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 22, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: Clancy Paul J (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$5.51	2030-07-22	Common Stock (23364)		Direct
Stock Option (right to buy)	$5.89	2031-03-10	Common Stock (34770)		Direct

Footnotes

F1: The option was granted on July 23, 2020 for 23,364 shares. On July 16, 2021, 25% of the shares underlying the option vested and the remainder are scheduled to vest in equal monthly installments thereafter until July 16, 2024.

F2: The option was granted on March 11, 2021 for 34,770 shares. On July 16, 2021, 25% of the shares underlying the option vested, and the remainder are scheduled to vest in equal monthly installments thereafter until July 16, 2024.